Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00679640
NCT00679640CompletedNot Applicable

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

AstraZeneca1 site in 1 country450 target enrollmentStarted: January 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
450
Locations
1
Primary Endpoint
Profile of patients treated with candesartan for heart failure
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure

Exclusion Criteria

  • •patients included in a clinical trial the last 30 days before consultation
  • •patients unable to answer the questions for linguistic or cognitive reasons
  • •patients who will be difficult to follow during the one year study

Arms & Interventions

1

Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure

Intervention: Candesartan (Drug)

Outcomes

Primary Outcomes

Profile of patients treated with candesartan for heart failure

Time Frame: At inclusion

Secondary Outcomes

  • Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring(6 and 12 months after)
  • Percentage of patients stopping its treatment and reasons why(12 months after)
  • Percentage of hospitalisations due to heart failure and cardiovascular deaths(12 months after)

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)Congestive Heart Failure
NCT00634309AstraZeneca597
Completed
Phase 3
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)Congestive Heart Failure
NCT00634712AstraZeneca734
Completed
Phase 3
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)Congestive Heart Failure
NCT00634400AstraZeneca6,268
Completed
Phase 3
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.Heart Failure
NCT00775840Takeda22
Completed
Not Applicable
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)Hypertension
NCT02016183Takeda3,222
Observational Usage and Efficacy Study of... | Clinical Trial